trans-4-((4-ChloropyriMidin-2-yl)aMino)cyclohexanol
|
- $307 - $1226
- Product name: trans-4-((4-ChloropyriMidin-2-yl)aMino)cyclohexanol
- CAS: 1261233-60-6
- MF: C10H14ClN3O
- MW: 227.69
- EINECS:
- MDL Number:MFCD18380528
- Synonyms:trans-4-((4-ChloropyriMidin-2-yl)aMino)cyclohexanol;Cyclohexanol, 4-[(4-chloro-2-pyrimidinyl)amino]-, trans-
4 prices
Selected condition：
Brand
- Chemenu
- Crysdot
Package
- 100mg
- 250mg
- 1g
- ManufacturerChemenu
- Product numberCM167147
- Product descriptiontrans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95%
- Packaging1g
- Price$1147
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11311450
- Product descriptiontrans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+%
- Packaging100mg
- Price$307
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11311450
- Product descriptiontrans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+%
- Packaging250mg
- Price$490
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11311450
- Product descriptiontrans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+%
- Packaging1g
- Price$1226
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Chemenu | CM167147 | trans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95% | 1g | $1147 | 2021-12-16 | Buy |
| Crysdot | CD11311450 | trans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+% | 100mg | $307 | 2021-12-16 | Buy |
| Crysdot | CD11311450 | trans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+% | 250mg | $490 | 2021-12-16 | Buy |
| Crysdot | CD11311450 | trans-4-((4-Chloropyrimidin-2-yl)amino)cyclohexanol 95+% | 1g | $1226 | 2021-12-16 | Buy |
Properties
Boiling point :412.8±55.0 °C(Predicted)
Density :1.365±0.06 g/cm3(Predicted)
pka :15.04±0.40(Predicted)
Density :1.365±0.06 g/cm3(Predicted)
pka :15.04±0.40(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|